ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

707
Analysis
Health Care • China
Wuxi Biologics is a global Contract Research, Development, and Manufacturing Organization (CRDMO) offering end-to-end solutions for biologics discovery, development, and manufacturing, including complex modalities like monoclonal antibodies and antibody-drug conjugates. The company provides comprehensive services from concept to commercialization, including vaccine CRDMO services. It was founded in 2010 and is headquartered in Wuxi, China.
more
bullish•Quantitative Analysis
•21 Jun 2026 10:45

Hong Kong Buybacks Weekly (Jun 18th): Tencent, Li Auto, Xiaomi

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
115 Views
Share
•12 May 2020 09:23

EM Strategy and Chartbook: Remain Overweight EM Vs. EAFE

China (MSCI China, Shanghai Comp., Shenzhen A Share) continues to offer many attractive setups and is a major focus in today’s EM Strategy report....

Logo
460 Views
Share
•29 Jan 2020 07:51

EM Pullback Opportunity

Supporting our global bull market thesis, uptrends remain intact for the major global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM). At this point,...

Logo
622 Views
Share
bullish•Quantitative Analysis
•12 Jun 2026 10:35

Hong Kong Buybacks Weekly (Jun 12th): Tencent, AIA, Xiaomi, Gcl Tech, J&T Express

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
129 Views
Share
bullish•Quantitative Analysis
•05 Jun 2026 10:59

Hong Kong Buybacks Weekly (Jun 5th): AIA, Tencent, Xiaomi, Li Auto, Mnso

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were AIA (1299 HK),...

Logo
130 Views
Share
x